Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. (NASDAQ: SNES) generates news as a biotechnology company focused on fertility control for rodent management. Its announcements frequently highlight developments related to ContraPest®, Evolve Rat, and Evolve Mouse Birth Control, which are described as contraceptive products for rats and mice that fit into integrated pest management programs and reduce reliance on traditional rodenticides.
Investors and observers following SNES news will see regular updates on financial performance and growth in Evolve rodent birth control products. Quarterly press releases report record revenues, gross profit margins, and the share of revenue contributed by Evolve-branded products, as well as commentary on adjusted EBITDA and cash balances. These releases often discuss progress toward profitability and the impact of multi-channel distribution strategies.
Company news also covers operational and commercial milestones. Examples include the launch of Evolve Rat Birth Control on major e-commerce platforms and home improvement retailer websites, expanded retail coverage through partners and wholesalers, and municipal pilot deployments in U.S. cities. Additional updates describe international distribution relationships, such as the appointment of the Belize Raptor Center as an official distributor following regulatory approval in Belize.
Regulatory and capital markets activities appear in SenesTech’s news flow as well. The company issues press releases on warrant exercises, gross proceeds from financings, and participation in investor conferences. For readers tracking SNES, this news page offers a way to monitor how SenesTech reports on product adoption, distribution channels, municipal and community programs, and financing events over time.
SenesTech (NASDAQ: SNES) closed a public offering of 1,428,572 shares at $3.50 each, generating approximately $5 million in gross proceeds. The offering included Series A and Series B warrants, both with an exercise price of $3.165, expiring five years and thirteen months respectively. Proceeds will be utilized for general corporate purposes. Additionally, existing warrants were amended to reduce their exercise price to $3.165 per share. The offering was facilitated by H.C. Wainwright & Co.
SenesTech (NASDAQ: SNES) announced a public offering of up to 1,428,572 shares at $3.50 each, intending to raise approximately $5 million before expenses. This offering includes Series A and Series B warrants at an exercise price of $3.165. The public offering is scheduled to close around November 18, 2022, with proceeds aimed for general corporate purposes. Additionally, existing warrants will be amended to align with the new exercise price. H.C. Wainwright & Co. is the exclusive placement agent.
SenesTech (NASDAQ: SNES) announced a 1-for-20 reverse stock split effective November 15, 2022. This action will reduce the total shares from approximately 12.2 million to about 610,648. The stock will trade on a split-adjusted basis starting November 16, 2022. The reverse split was approved by shareholders on October 12, 2022, to potentially increase the stock price and maintain compliance with Nasdaq listing requirements. This measure aims to improve shareholder value and align the company's stock with market expectations.
SenesTech, Inc. (NASDAQ: SNES) reported significant growth in its third quarter 2022 results, with product sales increasing by 57% year-over-year. Total revenue reached approximately $250,000, a 36% rise from Q3 2021. The company's e-commerce platform grew by 173%, contributing over 50% of sales. Despite these gains, the net loss widened to $(2.6) million from $(2.3) million in Q3 2021. New CEO Joel Fruendt emphasized sustainability in pest management. Challenges included delays in product deployment due to avian influenza affecting poultry operations.
SenesTech, Inc. (NASDAQ: SNES) has appointed Joel Fruendt as its new Chief Executive Officer, succeeding Ken Siegel, who will retire at the year's end while remaining as an Executive Director during the transition. Fruendt brings over 15 years of experience in the pest control industry, previously holding senior roles at Clarke Environmental Inc. and a global manufacturing firm. His appointment aligns with SenesTech's strategy to enhance the commercialization of ContraPest, its EPA-registered rodent fertility control product, aiming for sustainable pest management solutions.
SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the third quarter of 2022, ending September 30, 2022, on November 14, 2022, before market open. A conference call will follow at 11:00 am ET to discuss the findings. The company focuses on innovative pest control through its patented product, ContraPest, designed to manage rat populations sustainably. Stakeholders can access the call via phone or live webcast and will have a replay option for later review.
SenesTech, Inc. (NASDAQ: SNES) will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company specializes in managing animal pest populations through fertility control, particularly focusing on rat populations. A webcast of their presentation will be available at 9:00am ET on September 28, and it will be archived for later replay. Additionally, management will hold virtual one-on-one meetings during the conference. SenesTech is known for ContraPest, the first U.S. EPA-registered rodent contraceptive.
SenesTech, Inc. (NASDAQ: SNES) has declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock for each outstanding share of common stock held as of September 5, 2022. This Series C Preferred Stock will have significant voting rights concerning amendments to the company's charter. Unvoted shares will be redeemed for $0.001 in cash. The company plans to file a report with the SEC and a special meeting notice regarding a potential reverse stock split. SenesTech is known for its eco-friendly rodent fertility control product, ContraPest.
SenesTech, Inc. (NASDAQ: SNES) reported record second quarter 2022 product sales, achieving a 73% year-over-year increase and a 42% sequential rise. Sales reached approximately $277,000, driven by e-commerce growth, including a boost from the Ecosystems Protection Act of 2021. The launch of the Elevate Bait System contributed to this surge, with 1,500 units shipped in just nine days. Despite a net loss of $(2.6 million), gross profit improved to 49%. The company anticipates continued growth in diverse segments, including zoos and agricultural markets.
SenesTech (NASDAQ: SNES) announced significant efficacy results for its contraceptive product, ContraPest, in zoo deployments. Following its use starting in December 2021, a major U.S. zoo reported a dramatic decrease in rat populations, allowing successful breeding of endangered birds for the first time in years. ContraPest has shown up to 90% efficacy improvement over traditional pest management methods. SenesTech has expanded its zoo customer base by over 300% in the past year, presenting a multimillion-dollar growth opportunity.